Tumor cell lines have exhibited multiple resistance mechanisms to rituximab, including complement inhibition via upregulation of CD55 and CD59, internalization of CD20 complexes, and alteration of pro-apoptotic and anti-apoptotic pathways [73,74,75,76]. The gene discussed is MS4A1; the disease is neoplasm.